CoChat

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 15 of the 42 sources its claims cite were checked for support.

Abstract

Targeting the KRAS pathway is a promising but challenging approach for colorectal cancer therapy. Despite showing potent efficacy in BRAF-mutated melanoma, MEK inhibitors appeared to be tolerated by colorectal cancer cells due to their intrinsic compensatory signaling. Here, we performed genome-wide CRISPR/Cas9 screening in the presence of MEK inhibitor to identify genes that are synthetically lethal with MEK inhibition in CRC models harboring KRAS mutations. Several genes were identified as potential functional drivers, which were significantly enriched in the GRB7-mediated RTK pathway. Loss-of-function and gain-of-function assays validated that GRB7 potently rendered CRC cells primary resistance to MEK inhibitors through the RTK pathway. Mass spectrum analysis of GRB7 immunoprecipitates revealed that PLK1 was the predominant interacting kinase of GRB7. Inhibition of PLK1 suppressed downstream signaling of RTK, including FAK, STAT3, AKT, and 4EBP1. The combination of PLK1 and MEK inhibitors synergistically inhibited CRC cell proliferation and induced apoptosis in vitro and in vivo. In conclusion, we identified GRB7-PLK1 as a pivotal axis mediating RTKs, resulting in MEK inhibitor tolerance. PLK1 is therefore a promising target for synergizing MEK inhibitors in the clinical treatment of CRC patients harboring KRAS mutations.

Overview

CoChat Summary

TL;DR

Genome-wide CRISPR/Cas9 knockout screening in KRAS-mutant colorectal cancer cells identified GRB7 as a key RTK-pathway driver of MEK inhibitor resistance. GRB7 acts through PLK1 recruitment to sustain downstream RTK signaling, and combined PLK1/MEK inhibition synergistically suppressed CRC growth in vitro and in an HCT116 xenograft model.

Key findings

  • In HCT116 cells, genome-wide CRISPR/Cas9 screening with AZD6244 identified sgRNAs targeting 1846 genes significantly depleted under MEK inhibition; enriched pathways included transmembrane receptor protein tyrosine kinase signaling, NF-κB, TGF-β, and extrinsic apoptotic regulation.
  • GRB7 was the most negatively selected RTK-pathway gene: 5 of 6 GRB7-targeting sgRNAs were consistently decreased in AZD6244-treated cells. GRB7 was upregulated in 11 of 14 patient-matched CRC biopsies, and high GRB7 was associated with poor disease-free survival in TCGA colon cancer data.
  • GRB7 knockdown sensitized HCT116, SW480, and LS174T cells to AZD6244, while GRB7 overexpression conferred resistance; GRB7 knockdown reduced PLK1 by ~40% at both protein and mRNA levels. IP-MS found 57 GRB7-interacting proteins enriched at least threefold, with PLK1 top-ranked.
  • Combining PLK1 inhibition (BI-2536 or shPLK1) with MEK inhibition synergistically induced apoptosis and suppressed 2D/3D CRC models; in HCT116 xenografts, AZD6244 plus BI-2536 was more potent than either alone, with reduced Ki67 and increased Tunel staining.

Methods

  • Genome-wide CRISPR/Cas9 knockout screen using the human GeCKO two-vector lentivirus system in Cas9-expressing HCT116 cells at MOI ~0.3 and ~500× sgRNA coverage; cells were treated with DMSO or AZD6244 for 7 days, followed by sgRNA sequencing.
  • Parallel transcriptomic profiling of HCT116 cells ± AZD6244, GO enrichment, GSEA, TCGA analyses, IHC of patient biopsies, and correlation analyses.
  • Functional validation used shRNA knockdown, GRB7 overexpression, clonogenic and MTT assays, Annexin V/PI apoptosis assays, western blot, co-immunoprecipitation, immunofluorescence, IP-MS, 3D spheroid culture, and HCT116 xenograft experiments; statistical tests included Student’s t test, Wilcoxon test, log-rank test, Pearson correlation, and Benjamini & Hochberg correction.

Limitations

  • Stated in the paper: effective GRB7 inhibitors are unavailable in the clinic, and the detailed regulatory mechanism of GRB7 needs to be illustrated; further research is needed to demonstrate GRB7’s role in regulating DUSPs, and the detailed function of the PLK1 family in MEK inhibitor resistance requires further investigation.
  • Evident from the text: the primary CRISPR screen was performed in a single KRAS-mutant CRC cell line (HCT116), with validation in a limited set of CRC lines and one xenograft model; GRB7 was targeted genetically rather than pharmacologically, and the combination strategy relied on the PLK1 inhibitor BI-2536 rather than a direct GRB7 inhibitor.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41388-021-02077-w

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 CRISPR library screening identifying the involvement of the RTKs pathway in MEKi resistance in KRAS mutation colon cancer cells. A Outline of genome-wide CRISPR/Cas9 knockout library screening in CRC cells. B Gene Ontology (GO) enrichment analysis of significantly downregulated genes in HCT116 cells treated with AZD6244. The Benjamini & Hochberg (BH) method was used for multiple comparison. C Heatmap of RTK genes in CRC cells treated with MEKi compared with DMSO control in GEO datasets. D Heatmap of RTKs genes in CRC cells treated with AZD6244 for 7 days. E GSEA analysis of the transmembrane receptor protein tyrosine kinase signaling pathway gene set in CRC cells treated with or without MEKi; datasets were from (C) and (D). p value and adjusted p value were determined by permutation test and Benjamini & Hochberg (BH) method, respectively. NES normalized enrichment score.
Fig. 1 CRISPR library screening identifying the involvement of the RTKs pathway in MEKi resistance in KRAS mutation colon cancer cells. A Outline of genome-wide CRISPR/Cas9 knockout library screening in CRC cells. B Gene Ontology (GO) enrichment analysis of significantly downregulated genes in HCT116 cells treated with AZD6244. The Benjamini & Hochberg (BH) method was used for multiple comparison. C Heatmap of RTK genes in CRC cells treated with MEKi compared with DMSO control in GEO datasets. D Heatmap of RTKs genes in CRC cells treated with AZD6244 for 7 days. E GSEA analysis of the transmembrane receptor protein tyrosine kinase signaling pathway gene set in CRC cells treated with or without MEKi; datasets were from (C) and (D). p value and adjusted p value were determined by permutation test and Benjamini & Hochberg (BH) method, respectively. NES normalized enrichment score.CC BY · PubMed Central
Fig. 2 GRB7 was the determent in the RTK pathway for MEKi resistance. A Scatter plot showing the genes that were enriched in the RTK pathway. The top ten downregulated genes based on log2(fold change) are represented. The size of the point represents the number of identified downregulated sgRNA sequences for each gene. B The sgRNAs targeting GRB7 were consistently depleted in AZD6244-treated cells. The Student’s t test was used to determine the p value. C Boxplot of GRB7 expression in normal and tumor tissues of colon cancer patient samples with or without the BRAF mutation and KRAS mutations from TCGA-COAD. The Wilcoxon test was used to determine the p value. D, E Representative immunohistochemical images of GRB7 staining in normal and tumor tissues from colon cancer patients. Scale bar, 200 μM. E Quantification of (D). Data represented as mean ± SD (n = 14). The Wilcoxon test was used to determine the p value. F Kaplan-Meier survival analysis of the association of GRB7 levels with disease-free survival (DFS) of colon cancer patients. Patients were divided into low or high groups according to the expression of GRB7. The log-rank test was used to determine the p value. G GRB7 mRNA expression was increased in AZD6244-treated cells. Datasets were from Fig. 1C, D. The Wilcoxon test was used to determine the p value. Batch effects between different datasets were removed by ComBat. H Cell cytoplasm/nucleus fractionation and western blot analysis to show GRB7 translocation with AZD6244 treatment. HCT116 cells treated with AZD6244 were fractionated into nuclear and cytoplasmic fractions at the indicated time points. *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001; TCGA-COAD The Cancer Genome Atlas Colon Adenocarcinoma.
Fig. 2 GRB7 was the determent in the RTK pathway for MEKi resistance. A Scatter plot showing the genes that were enriched in the RTK pathway. The top ten downregulated genes based on log2(fold change) are represented. The size of the point represents the number of identified downregulated sgRNA sequences for each gene. B The sgRNAs targeting GRB7 were consistently depleted in AZD6244-treated cells. The Student’s t test was used to determine the p value. C Boxplot of GRB7 expression in normal and tumor tissues of colon cancer patient samples with or without the BRAF mutation and KRAS mutations from TCGA-COAD. The Wilcoxon test was used to determine the p value. D, E Representative immunohistochemical images of GRB7 staining in normal and tumor tissues from colon cancer patients. Scale bar, 200 μM. E Quantification of (D). Data represented as mean ± SD (n = 14). The Wilcoxon test was used to determine the p value. F Kaplan-Meier survival analysis of the association of GRB7 levels with disease-free survival (DFS) of colon cancer patients. Patients were divided into low or high groups according to the expression of GRB7. The log-rank test was used to determine the p value. G GRB7 mRNA expression was increased in AZD6244-treated cells. Datasets were from Fig. 1C, D. The Wilcoxon test was used to determine the p value. Batch effects between different datasets were removed by ComBat. H Cell cytoplasm/nucleus fractionation and western blot analysis to show GRB7 translocation with AZD6244 treatment. HCT116 cells treated with AZD6244 were fractionated into nuclear and cytoplasmic fractions at the indicated time points. *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001; TCGA-COAD The Cancer Genome Atlas Colon Adenocarcinoma.CC BY · PubMed Central
Fig. 3 GRB7 is sufficient for MEKi resistance in KRAS mutation colon cancer cells. A Clonogenic assay showing that knockdown of GRB7 with shRNAs enhanced response to MEKi. B Short-term survival curves identifying that knockdown of GRB7 increased the sensitivity of MEKi. Results are shown relative to DMSO-treated controls (mean ± SD, n = 5; dashed line, 50% inhibition). C–F Knockdown of GRB7 significantly induced apoptosis upon AZD6244 treatment in HCTT16 (C, D) and SW480 (E, F). Cells were treated with AZD6244 for 48 h (HCT116) or 24 h (SW480). Data represented as mean ± SD (n = 3). G–I Clonogenic assay showing that GRB7 overexpression conferred resistance to AZD6244. (H) Quantification of HCT116, (I) Quantification of SW480. Data represented as mean ± SD (n = 3). J, K Induction of anti-apoptosis upon overexpression of GRB7 in HCT116. K Quantification of (J). Data represented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.
Fig. 3 GRB7 is sufficient for MEKi resistance in KRAS mutation colon cancer cells. A Clonogenic assay showing that knockdown of GRB7 with shRNAs enhanced response to MEKi. B Short-term survival curves identifying that knockdown of GRB7 increased the sensitivity of MEKi. Results are shown relative to DMSO-treated controls (mean ± SD, n = 5; dashed line, 50% inhibition). C–F Knockdown of GRB7 significantly induced apoptosis upon AZD6244 treatment in HCTT16 (C, D) and SW480 (E, F). Cells were treated with AZD6244 for 48 h (HCT116) or 24 h (SW480). Data represented as mean ± SD (n = 3). G–I Clonogenic assay showing that GRB7 overexpression conferred resistance to AZD6244. (H) Quantification of HCT116, (I) Quantification of SW480. Data represented as mean ± SD (n = 3). J, K Induction of anti-apoptosis upon overexpression of GRB7 in HCT116. K Quantification of (J). Data represented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.CC BY · PubMed Central
Fig. 4 GRB7 conferred resistance to MEKi through regulation of downstream RTK pathway. A Western blot analysis showed that combinational inhibition of GRB7 and MEK suppressed the downstream effectors in RTK pathway. HCT116 and SW480 were infected with shRNA4 targeting GRB7 or vector control. After infection, cells were treated with AZD6244 for 24 h. Cell lysates were made for immunoblot analysis with antibodies indicated. ACTIN is as loading control. B Overexpression of GRB7 activated RTK pathway. HCT116 were ectopically expressed GRB7 or vector control. After infection, cells were treated with AZD6244 for 24 h. Cell lysates were made for immunoblot analysis with antibodies indicated. ACTIN is as loading control. C–F Knockdown of GRB7 impaired HGF/EGF-dependent pathway. HCT116 were infected with shRNA4 targeting GRB7 or vector control. After infection, cells were treated with 20 ng/mL HGF(C) or EGF (E) for the indicated time. Cell lysates were made for immunoblot with antibodies indicated. ACTIN is as loading control. D Quantification of (C). F Quantification of (E). G GRB7 interacted with RTKs directly. Cell lysates from GRB7 expressing or vector control cells were subjected to immunoprecipitation with Flag antibody or immunoglobulin G control. The immunoprecipitants (left) or cell lysates (right) were then blotted with the indicated antibodies. H Representative immunofluorescence images of GRB7 in HCT116 treated with 20 ng/mL HGF for indicated time. Scale bar, 20 μM. I Quantification of (H). *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.
Fig. 4 GRB7 conferred resistance to MEKi through regulation of downstream RTK pathway. A Western blot analysis showed that combinational inhibition of GRB7 and MEK suppressed the downstream effectors in RTK pathway. HCT116 and SW480 were infected with shRNA4 targeting GRB7 or vector control. After infection, cells were treated with AZD6244 for 24 h. Cell lysates were made for immunoblot analysis with antibodies indicated. ACTIN is as loading control. B Overexpression of GRB7 activated RTK pathway. HCT116 were ectopically expressed GRB7 or vector control. After infection, cells were treated with AZD6244 for 24 h. Cell lysates were made for immunoblot analysis with antibodies indicated. ACTIN is as loading control. C–F Knockdown of GRB7 impaired HGF/EGF-dependent pathway. HCT116 were infected with shRNA4 targeting GRB7 or vector control. After infection, cells were treated with 20 ng/mL HGF(C) or EGF (E) for the indicated time. Cell lysates were made for immunoblot with antibodies indicated. ACTIN is as loading control. D Quantification of (C). F Quantification of (E). G GRB7 interacted with RTKs directly. Cell lysates from GRB7 expressing or vector control cells were subjected to immunoprecipitation with Flag antibody or immunoglobulin G control. The immunoprecipitants (left) or cell lysates (right) were then blotted with the indicated antibodies. H Representative immunofluorescence images of GRB7 in HCT116 treated with 20 ng/mL HGF for indicated time. Scale bar, 20 μM. I Quantification of (H). *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.CC BY · PubMed Central
Fig. 5 RTK pathway activated by GRB7 through PLK1. A Dot plot revealing that PLK1 was the most upregulated protein in colon cancer tissues from TCGA data of the top five GRB7-interacting proteins. The y-axis represents the log2 fold change of FPKM between tumor and normal tissues in the TCGA-COAD. The x-axis represents the log2 fold change of unique peptides between HCT116 expressing FLAG-GRB7 and control cells by MS. The top five genes are displayed in red according to the unique peptides. B, C Immunohistochemical images of PLK1 staining in normal and tumor tissues from colon cancer patients. Scale bar, 200 μM. C Quantification of (B). Data represented as mean ± SD (n = 14). The Wilcoxon test was used to determine the p value. D, E GRB7 interacted with PLK1 and RPTOR directly. Cell lysates from HCT116 expressing GRB7 or vector control were subjected to immunoprecipitation with Flag antibody (D) or PLK1 antibody (E) or immunoglobulin G control. The immunoprecipitants or cell lysates were then blotted with the indicated antibodies. F Representative immunofluorescence images for GRB7 and PLK1 in HCT116 expressing GRB7 or vector control. Scale bar, 20 μM. G HCT116 cells were infected with shRNAs targeting GRB7 or vector control. Cells were collected for qPCR analysis (top) or cell lysates were made for immunoblot against indicated antibodies (bottom). Data represented as mean ± SD (n = 3). H GRB7 promoted the interactions between PLK1 and RTK effectors. HCT116 were infected with vector or GRB7 overexpressing plasmid. The cell lysates were immunoprecipitated with an anti-PLK1 antibody, and the precipitates were analyzed by western blot analysis with the indicated antibodies. I Western blot analysis showing that combinational inhibition of PLK1 and MEK suppresses the downstream effectors in the RTKs pathway. HCT116 were infected with shRNAs targeting PLK1 or vector control. Actin was used as the control. J Western blot analysis of downstream RTK signaling inhibition after AZD6244 with BI-2536 treatment for 24 h in HCT116. K Immunoblot analysis of cell lysates, using the indicated antibodies, of HCT116 overexpressing vector alone, FLAG-GRB7, shPLK1, or FLAG-GRB7 plus shPLK1. L, M Expression correlation analysis of mRNA of GRB7 with PLK1 (L), RPTOR (M) using RNAseq data of TCGA-COAD samples. The scatter plots show the Pearson correlation of GRB7 with PLK1, RPTOR, and the significance of their correlation is tested by Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.
Fig. 5 RTK pathway activated by GRB7 through PLK1. A Dot plot revealing that PLK1 was the most upregulated protein in colon cancer tissues from TCGA data of the top five GRB7-interacting proteins. The y-axis represents the log2 fold change of FPKM between tumor and normal tissues in the TCGA-COAD. The x-axis represents the log2 fold change of unique peptides between HCT116 expressing FLAG-GRB7 and control cells by MS. The top five genes are displayed in red according to the unique peptides. B, C Immunohistochemical images of PLK1 staining in normal and tumor tissues from colon cancer patients. Scale bar, 200 μM. C Quantification of (B). Data represented as mean ± SD (n = 14). The Wilcoxon test was used to determine the p value. D, E GRB7 interacted with PLK1 and RPTOR directly. Cell lysates from HCT116 expressing GRB7 or vector control were subjected to immunoprecipitation with Flag antibody (D) or PLK1 antibody (E) or immunoglobulin G control. The immunoprecipitants or cell lysates were then blotted with the indicated antibodies. F Representative immunofluorescence images for GRB7 and PLK1 in HCT116 expressing GRB7 or vector control. Scale bar, 20 μM. G HCT116 cells were infected with shRNAs targeting GRB7 or vector control. Cells were collected for qPCR analysis (top) or cell lysates were made for immunoblot against indicated antibodies (bottom). Data represented as mean ± SD (n = 3). H GRB7 promoted the interactions between PLK1 and RTK effectors. HCT116 were infected with vector or GRB7 overexpressing plasmid. The cell lysates were immunoprecipitated with an anti-PLK1 antibody, and the precipitates were analyzed by western blot analysis with the indicated antibodies. I Western blot analysis showing that combinational inhibition of PLK1 and MEK suppresses the downstream effectors in the RTKs pathway. HCT116 were infected with shRNAs targeting PLK1 or vector control. Actin was used as the control. J Western blot analysis of downstream RTK signaling inhibition after AZD6244 with BI-2536 treatment for 24 h in HCT116. K Immunoblot analysis of cell lysates, using the indicated antibodies, of HCT116 overexpressing vector alone, FLAG-GRB7, shPLK1, or FLAG-GRB7 plus shPLK1. L, M Expression correlation analysis of mRNA of GRB7 with PLK1 (L), RPTOR (M) using RNAseq data of TCGA-COAD samples. The scatter plots show the Pearson correlation of GRB7 with PLK1, RPTOR, and the significance of their correlation is tested by Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.CC BY · PubMed Central
Fig. 6 Combined genetic or pharmacologic inhibition of PLK1 and MEKi treatment promoted apoptosis in KRAS mutant colon cancer cells. A, B Knockdown of PLK1 by shRNAs induced apoptosis upon AZD6244 treatment in HCT116. B Quantification of (A). Data represented as mean ± SD (n = 3). C, D Apoptosis assay showing that BI-2536 sensitized HCT116 cells to AZD6244. D Quantification of (C). Data represented as mean ± SD (n = 3). E HCT116 cells infected with shRNA targeting GRB7 or vector control, then treated with or without BI-2536 in the presence of 1 μM AZD6244 for 48 h. Data represented as mean ± SD (n = 3). F HCT116 cells infected with vector control, Flag-GRB7, shRNA targeting PLK1, or the combination of both, then treated with 10 μM AZD6244 for 48 h. Apoptosis was detected by annexin V/PI staining. Data represented as mean ± SD (n = 3). G–I Representative phase-contrast and immunofluorescence staining images of HCT116 treated with DMSO, AZD6244, BI-2536, or the combination of both for 8 days in 3D culture system (CaM: green; PI: red). Scale bar, 100 μM. H Quantification of spheroid area. I Quantification of spheroid number. J–L Representative phase-contrast and immunofluorescence staining images of SW480 treated with DMSO, GSK, BI-2536, or the combination of both for 8 days in 3D culture system (CaM: green; PI: red). Scale bar, 100 μM. K Quantification of spheroid area. L Quantification of spheroid number. *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.
Fig. 6 Combined genetic or pharmacologic inhibition of PLK1 and MEKi treatment promoted apoptosis in KRAS mutant colon cancer cells. A, B Knockdown of PLK1 by shRNAs induced apoptosis upon AZD6244 treatment in HCT116. B Quantification of (A). Data represented as mean ± SD (n = 3). C, D Apoptosis assay showing that BI-2536 sensitized HCT116 cells to AZD6244. D Quantification of (C). Data represented as mean ± SD (n = 3). E HCT116 cells infected with shRNA targeting GRB7 or vector control, then treated with or without BI-2536 in the presence of 1 μM AZD6244 for 48 h. Data represented as mean ± SD (n = 3). F HCT116 cells infected with vector control, Flag-GRB7, shRNA targeting PLK1, or the combination of both, then treated with 10 μM AZD6244 for 48 h. Apoptosis was detected by annexin V/PI staining. Data represented as mean ± SD (n = 3). G–I Representative phase-contrast and immunofluorescence staining images of HCT116 treated with DMSO, AZD6244, BI-2536, or the combination of both for 8 days in 3D culture system (CaM: green; PI: red). Scale bar, 100 μM. H Quantification of spheroid area. I Quantification of spheroid number. J–L Representative phase-contrast and immunofluorescence staining images of SW480 treated with DMSO, GSK, BI-2536, or the combination of both for 8 days in 3D culture system (CaM: green; PI: red). Scale bar, 100 μM. K Quantification of spheroid area. L Quantification of spheroid number. *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.CC BY · PubMed Central
Fig. 7 Combination of PLK1i and MEKi synergically suppresses CRC tumor growth. A BALB/c Nude mice were subcutaneously inoculated with 3 × 106 HCT116 cells on day 0. Tumor-bearing mice (n = 5) were treated with vehicle, AZD6244, BI-2536, or the combination when the tumor volume achieved ≈100 mm3. B Tumor growth curves for mice treated with vehicle, AZD6244, BI-2536, or the combination. C Tumor volume of xenograft tumors on day 26. Data represented as mean ± SD (n = 10). D Representative image of mice and tumors with different treatments on day 26. (E) Weights of xenograft tumors on day 26. Data represented as mean ± SD (n = 10). F–H Representative immunohistochemical images of Ki67 and Tunel staining in tumors from each group. Scale bar, 400 μM. G Quantification of Ki67+ cells. Data represented as mean ± SD (n = 5). H Quantification of Tunel+ cells. Data represented as mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.
Fig. 7 Combination of PLK1i and MEKi synergically suppresses CRC tumor growth. A BALB/c Nude mice were subcutaneously inoculated with 3 × 106 HCT116 cells on day 0. Tumor-bearing mice (n = 5) were treated with vehicle, AZD6244, BI-2536, or the combination when the tumor volume achieved ≈100 mm3. B Tumor growth curves for mice treated with vehicle, AZD6244, BI-2536, or the combination. C Tumor volume of xenograft tumors on day 26. Data represented as mean ± SD (n = 10). D Representative image of mice and tumors with different treatments on day 26. (E) Weights of xenograft tumors on day 26. Data represented as mean ± SD (n = 10). F–H Representative immunohistochemical images of Ki67 and Tunel staining in tumors from each group. Scale bar, 400 μM. G Quantification of Ki67+ cells. Data represented as mean ± SD (n = 5). H Quantification of Tunel+ cells. Data represented as mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.CC BY · PubMed Central
Fig. 8 A proposed model depicting the therapeutic mechanism of GRB7-PLK1 axis inhibition to overcome MEKi resistance in KRAS mutant colon cancer cells. A In KRAS mutant CRC cells, GRB7 confers MEKi resistance through mediating the RTK pathway. B Combination AZD6244 and GRB7-PLK1 axis inhibition significantly suppresses the proliferation and induces apoptosis through attenuating RTK signaling.
Fig. 8 A proposed model depicting the therapeutic mechanism of GRB7-PLK1 axis inhibition to overcome MEKi resistance in KRAS mutant colon cancer cells. A In KRAS mutant CRC cells, GRB7 confers MEKi resistance through mediating the RTK pathway. B Combination AZD6244 and GRB7-PLK1 axis inhibition significantly suppresses the proliferation and induces apoptosis through attenuating RTK signaling.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 1 Not valid · 14 Not checked · 101 Own results and interpretations

89 more claims

Create a free account to see all 127 claims and to verify the 27 references still open.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Cited by

See all 70

Metadata

Authors
Yu, C., Luo, D., Yu, J., Zhang, M., Zheng, X., Xu, G., Wang, J., Wang, H., Xu, Y., Jiang, K., Xu, J., Ma, X., Jing, J., & Shi, H.
Affiliations
  • Sichuan University (CN)
  • Chengdu Medical College (CN)
  • Zunyi Medical University (CN)
  • Sun Yat-sen University Cancer Center (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
  • Jing, Jing
  • Shi, Hubing
Venue
Oncogene
Published
2021-10-30
Volume
41
Issue
2
Pages
191-203
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W3207988094
Cited by
70
References
45
Citations by year
2026: 6 · 2025: 10 · 2024: 25 · 2023: 16 · 2022: 12 · 2021: 1
FWCI
5.01
Type
journal article
Language
en
Open access
Licence
Locations
  • Oncogene (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81773752)
  • National Science Foundation of China | Key Programme (2016YFC0906000 [2016YFC0906003)
  • National Science Foundation of China | Young Scientists Fund (31801143, 81902793, 81803574)
  • China Postdoctoral Science Foundation (2019M653430)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
Grb7, MEK inhibitor resistance, KRAS mutation, colorectal cancer, PLK1, receptor tyrosine kinase signaling, synthetic lethality, CRISPR-Cas9 screen, drug resistance, combination therapy, STAT3, Akt, focal adhesion kinase, 4E-BP1, apoptosis
MeSH terms
Animals, Colonic Neoplasms, Humans, Signal Transduction, Cell Line, Tumor, Cell Proliferation, Mice, Early Detection of Cancer, Genome-Wide Association Study, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. https://app.cochat.ai/papers/10.1038/s41388-021-02077-w
The paper
Yu, C., Luo, D., Yu, J., Zhang, M., Zheng, X., Xu, G., Wang, J., Wang, H., Xu, Y., Jiang, K., Xu, J., Ma, X., Jing, J., & Shi, H. (2022). Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. Oncogene. https://doi.org/10.1038/s41388-021-02077-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.